Michael Castagna - May 15, 2024 Form 4 Insider Report for MANNKIND CORP (MNKD)

Role
Chief Executive Officer, Director
Signature
/s/ Michael Castagna
Stock symbol
MNKD
Transactions as of
May 15, 2024
Transactions value $
-$240,395
Form type
4
Date filed
5/17/2024, 09:00 PM
Previous filing
May 14, 2024
Next filing
May 21, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MNKD Common Stock, $.01 Par Value Award $0 +465K +21.64% $0.00 2.61M May 15, 2024 Direct F1, F2
transaction MNKD Common Stock, $.01 Par Value Other -$124K -28.7K -1.1% $4.32 2.59M May 17, 2024 Direct F3
transaction MNKD Common Stock, $.01 Par Value Other -$117K -24.3K -0.94% $4.79 2.56M May 17, 2024 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNKD Performance Restricted Stock Unit Award $0 +569K $0.00 569K May 15, 2024 Common Stock, $.01 Par Value 569K Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
F2 Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2025 and each yearly anniversary thereof until fully vested.
F3 Reporting person transferred 28,670 shares of MNKD common stock to his ex-spouse pursuant to a divorce decree.
F4 Reporting person transferred 24,330 shares of MNKD common stock to his ex-spouse pursuant to a divorce decree.
F5 The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.